Journal of Oncology

Mitochondrial Quality Control for Targeted Cancer Therapy


Publishing date
01 Feb 2022
Status
Closed
Submission deadline
01 Oct 2021

Lead Editor

1Chinese PLA General Hospital, Beijing, China

2Hebei University, Baoding, China

3University of Minnesota, Duluth, USA

4Chinese University of Hong Kong, Hong Kong

This issue is now closed for submissions.
More articles will be published in the near future.

Mitochondrial Quality Control for Targeted Cancer Therapy

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Cancer is currently one of the main diseases causing a high number of deaths per year. Therefore, there is an urgent need to understand better the diversity of tumors. Moreover, there is also a need to further initiate the development of effective therapeutic tools or combinations of currently existing medicines to target cancer in novel ways. Mitochondria are highly dynamic organelles that provide energy for cell growth, proliferation, differentiation, invasion, metastasis, survival, and death. When cells become cancerous, the morphology, cellular location, and metabolic mode of the mitochondria change accordingly. These mitochondrial changes can have two opposing effects on cancer: pro-cancer and anticancer effects. Specifically, mitochondria play roles in the fight against cancer by participating in processes such as ferroptosis, mitophagy, and antitumor immunity. Meanwhile, cancer cells can also enslave mitochondria to give them the conditions necessary for growth and metastasis. Moreover, through mitochondria, cancer cells can escape from immune surveillance, resulting in their immune escape and enhanced malignant transformation ability.

Understanding the complex role of mitochondria in cancer biology is critical and may help identify novel therapeutic and preventative strategies for malignant tumors. Mitochondrial quality control (MQC) is a group of adaptive responses that regulate mitochondrial protein turnover, mitochondrial biogenesis, mitochondrial fusion, mitochondrial fission, mitophagy, and mitochondria-dependent cell death. The main consequences of MQC are the rapid removal of defective mitochondrial debris and the timely replenishment of the mitochondrial network. These biophysical processes protect the mitochondria from damage and therefore contribute to tumorigenesis. When these adaptive responses fail, programmed cell death by apoptosis or necroptosis is activated, and damaged mitochondria become the inducers of cell death, enabling the sequestration of injured or dysfunctional cancer cells. However, the roles of MQC in tumorigenesis and/or cancer cell death have not been fully explored. Besides, given the important role played by mitochondria in cancer biology, it remains of outstanding interest to design, develop, and validate pharmacologic and non-pharmacologic preventive approaches for the treatment of cancer with a focus on MQC.

The aim of this Special Issue is to figure out the functional importance of MQC in cancer biology. It aims at spreading the knowledge that MQC participates in a number of biochemical pathways important for the survival or death of tumour cells. Submissions should consider MQC as a central target in therapeutics. We strongly encourage submissions of both original and review articles.

Potential topics include but are not limited to the following:

  • Innovative aspects of MQC (e.g., mitochondrial fission, fusion, mitophagy, and mitochondrial metabolism) in human cancers
  • Clinically relevant information on the effects of therapies for cancer with a focus on MQC
  • Recent advances in the knowledge and understanding of MQC in human cancers
  • Pharmacologic and non-pharmacologic preventive approaches with a MQC focus for cancer treatments

Articles

  • Special Issue
  • - Volume 2022
  • - Article ID 9119245
  • - Research Article

Hyperfractionation versus Conventional Fractionation of Preoperative Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: A Propensity Score Matching Study

Chen Shi | Yangzi Zhang | ... | Weihu Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 9913700
  • - Research Article

TMEM60 Promotes the Proliferation and Migration and Inhibits the Apoptosis of Glioma through Modulating AKT Signaling

Jingwen Wu | Xinghua Tang | ... | Qiuan Yang
  • Special Issue
  • - Volume 2021
  • - Article ID 9365953
  • - Research Article

DNA Damage Response Genes in Osteosarcoma

Ying Tang | Yan-xia Liu | ... | Peng Li
  • Special Issue
  • - Volume 2021
  • - Article ID 5070099
  • - Research Article

Development and Validation of a Novel Mitophagy-Related Gene Prognostic Signature for Hepatocellular Carcinoma Based on Immunoscore Classification of Tumor

Hao Chen | Jinghua Wang | ... | Zewei Zhuo
  • Special Issue
  • - Volume 2021
  • - Article ID 5212721
  • - Research Article

Yap-Hippo Signaling Activates Mitochondrial Protection and Sustains Breast Cancer Viability under Hypoxic Stress

Chen Shi | Siyuan Zhang | ... | Jian Tie
  • Special Issue
  • - Volume 2021
  • - Article ID 1262291
  • - Research Article

Mst2 Overexpression Inhibits Thyroid Carcinoma Growth and Metastasis by Disrupting Mitochondrial Fitness and Endoplasmic Reticulum Homeostasis

Haichao Zhang | Xin Qu | ... | Xu Di
  • Special Issue
  • - Volume 2021
  • - Article ID 1615201
  • - Research Article

Identification of the Novel Methylated Genes’ Signature to Predict Prognosis in INRG High-Risk Neuroblastomas

Zhichao Liu | Changchun Li
Journal of Oncology
 Journal metrics
See full report
Acceptance rate27%
Submission to final decision58 days
Acceptance to publication22 days
CiteScore4.000
Journal Citation Indicator0.680
Impact Factor4.375
 Submit

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.